Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login


Cardiovascular agents

Statins reduce risk of major vascular events in all ages, study finds

Statins reduce the risk of vascular events in people of all ages, although there is less evidence of this in people aged over 75 years than in younger patients, researchers have found.

A meta-analysis published in The Lancet (online, 2 February 2019) found that, irrespective of age, statins reduced the risk of major vascular events by 21% per 1mmol/L reduction in low-density lipoprotein (LDL) cholesterol. For major coronary events the overall reduction was 24% per 1 mmol/L reduction, but ranged from about 30% in people aged under 55 years to around 20% in people aged over 75 years.

The study looked at evidence from 28 randomised controlled trials, which included 186,854 patients — 14,483 of whom were aged over 75 years. It also found no adverse effects of statin therapy on nonvascular mortality or cancer.

Jordan Fulcher, a researcher at the Cholesterol Treatment Trialists’ Collaboration at the University of Sydney, which carried out the research, said his team had wanted to consider the evidence gap on the efficacy and safety of statins in older people.

“Our analysis indicates that major cardiovascular events were reduced by about a fifth, per mmol/L lower LDL cholesterol, by statin therapy across all age groups. Despite previous concerns, we found no adverse effect on cancer or nonvascular mortality in any age group,” he said.

Martin Marshall, vice chair of the Royal College of GPs, said it was “particularly reassuring to see evidence of benefit in patients over the age of 75 [years] — the age group most likely to need cholesterol medication, and who are at risk of heart attacks and strokes”.

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2019.20206095

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.